Design And Evaluation Of Meloxicam Tablet For Colon Cancer

Authors

  • Archana S Students, Department of Pharmacy, JDT Islam College Of Pharmacy, Calicut, Kerala, India
  • Dr Ibrahim Afsal V .T
  • Fathima Musthafal
  • Fathima PM
  • Ayisha Shafrin
  • Syamprasad PS

Keywords:

Meloxicam, COX 2 inhibitor, Colorectal cancer, Targeted drug delivery, Colon Cancer.

Abstract

Meloxicam, recognized as a preferential COX-2 inhibitor, has emerged as a promising chemopreventive agent for colorectal cancer. Leveraging its local and targeted action on the colon, Meloxicam proves to be a formidable component in the prevention of colorectal malignancies. This study aims to innovate by formulating and evaluating a targeted tablet delivery system for Meloxicam, emphasizing site-specific and instant drug release in the colon, thereby maximizing its therapeutic efficacy in the treatment of colorectal cancer. Acknowledging Meloxicam's challenges as an extremely poorly soluble acidic drug with pH-dependent solubility, the formulation incorporates buffering agents to ensure pH-independent drug release upon reaching the colon. In vitro evaluations of the coated tablets, containing 2% croscarmelose and 4% crospovidone as disintegrants, demonstrate immediate drug release within the colon. Notably, the tablet's drug content, standing at 96.9%, aligns with the standards outlined by the United States Pharmacopeia (USP). This substantiates the formulation's compliance with regulatory benchmarks, indicating its potential for clinical application. In conclusion, this study affirms the efficacy of the Meloxicam targeted tablet formulation, showcasing its potential as an advanced and targeted drug delivery system for the treatment of colorectal cancer.

References

Mayur M. Patel and Avani F. Amin, “Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer.”[ Drug Delivery 2011, 18(4), 281–293]

Anil K. Philip and Betty Philip, “Colon Targeted Drug Delivery Systems: A Review on Primary and Novel Approaches.” [Oman Medical Journal 2010, 25, 70-78]

Gurmeet Singh and Dinesh Kumar, “Emerging Techniques and Challenges in Colon Drug Delivery Systems.”[ Journal of Applied Pharmaceutical Science 2012, 02 (03), 139-147]

Malik K and Goswami L, “A Review on Colon Targeting Drug Delivery System: Novel Approaches, Anatomy and Evaluation.” [The pharma innovation 2012, 1-12]

Bhushan Prabhakar Kolte and Kalyani V. Tele, “Colon Targeted Drug Delivery System – A Novel Perspective.” [Asian Journal of Biomedical and Pharmaceutical Sciences 2012, 21-28]

Libo Yang and James S. Chu, “Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation.” [International Journal of Pharmaceutics 2002, 235, 1–15].

The United States Pharmacopoeia 32-NF27, USPC Board of Trustees, United States of America, 2008, Volume ш, 2610-2611.

http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1C/Step4/Q1C_Guideline.pdf.

http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Qua lity/Q1A_R2/Step4/Q1A_R2 Guideline.pdf.

Asha Patel and Nilam Bhatt, “Colon targeted drug delivery system: a review system.” [Journal of pharmaceutical science and bioscientific research 2011, 37- 49]

Downloads

Published

2024-01-12

Issue

Vol. 10 No. 3 (2023)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.